Urogen Pharma Ltd.
A biotech whose gel turns liquid to jelly at body heat, letting cancer drugs linger in the urinary tract for hours instead of minutes. Its FDA-approved treatments Jelmyto and Zusduri offer non-surgical options for rare bladder and kidney-tube cancers. Born in 2004 as Theracoat, it renamed itself UroGen in 2015 and won its first approval in 2020.
Granted 54.5K
Sold 209.3K
Granted 294.5K
Granted 358.7K · Bought 26.5K · Sold 55.2K
Granted 84.3K
Granted 209.5K · Bought 2.4K · Sold 161.4K
Granted 82.5K · Bought 2.5K · Sold 43.7K
Granted 5.8K
Granted 15.8K · Sold 6.3K
Granted 16.2K · Sold 6.1K
Granted 6.0K
Granted 5.7K · Bought 2.5K · Sold 2.9K
Granted 4.5K · Sold 2.2K
Granted 2.0K
Granted 2.0K
Granted 2.0K
Granted 2.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Nussbaum RanDirector · 5 transactions | — | 1.49Mas of Oct 2022 | 54.5K | — | — |
| Moorin Jay +3 co-filers10% owner · 2 transactions | — | 1.24Mas of Nov 2017 | — | — | 209.3K |
| Belldegrun ArieDirector · 4 transactions | — | 408.7Kas of Sep 2022 | 294.5K | — | — |
| Barrett Elizabeth A.Chief Executive Officer · 28 transactions | — | 313.4Kas of Jan 2023 | 358.7K | 26.5K | 55.2K |
| Cohen Fred EDirector · 2 transactions | — | 69.3Kas of Jul 2023 | 84.3K | — | — |
| Schoenberg MarkChief Medical Officer · 95 transactions | — | 59.1K | 209.5K | 2.4K | 161.4K |
| Smith Jason DrewGeneral Counsel · 34 transactions | — | 52.9K | 82.5K | 2.5K | 43.7K |
| Kim DongChief Financial Officer · 2 transactions | — | 37.8Kas of Sep 2024 | 5.8K | — | — |
| Pfreundschuh Peter P.Chief Financial Officer · 20 transactions | — | 11.8Kas of Oct 2020 | 15.8K | — | 6.3K |
| Mullennix StephenChief Operating Officer · 14 transactions | — | 10.1Kas of Apr 2020 | 16.2K | — | 6.1K |
| Robinson James A. Jr.Director · 3 transactions | — | 6.0K | 6.0K | — | — |
| Henderson MollyChief Financial Officer · 5 transactions | — | 5.6Kas of Jan 2022 | 5.7K | 2.5K | 2.9K |
| Degnan ChrisChief Financial Officer · 2 transactions | — | 2.3K | 4.5K | — | 2.2K |
| Butitta Cynthia MDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
| Holden StuartDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
| Wen LeanaDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
| Wildman Daniel GeorgeDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -453.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.